| scholarly article | Q13442814 |
| P2093 | author name string | Hayden FG | |
| Kaiser L | |||
| Gubareva LV | |||
| Matrosovich MN | |||
| Soo-Hoo Y | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | experimental infection | Q107184421 |
| oseltamivir | Q211509 | ||
| P304 | page(s) | 523-531 | |
| P577 | publication date | 2001-01-11 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir | |
| P478 | volume | 183 |
| Q30405350 | A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase |
| Q44497218 | A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding |
| Q30402874 | Adamantane- and oseltamivir-resistant seasonal A (H1N1) and pandemic A (H1N1) 2009 influenza viruses in Guangdong, China, during 2008 and 2009 |
| Q28483965 | Amino acids transitioning of 2009 H1N1pdm in Taiwan from 2009 to 2011 |
| Q39448750 | An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy |
| Q39198919 | Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system |
| Q30358429 | Antiviral agents active against influenza A viruses. |
| Q93238882 | Antiviral agents against respiratory viruses |
| Q34992622 | Antiviral prophylaxis and treatment (excluding HIV therapy). |
| Q30410899 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives |
| Q83225274 | Antiviral treatment of influenza A (H1N1-09) guided by molecular resistance testing in aplasia after allo-SCT |
| Q38633113 | Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies |
| Q33385043 | Aurintricarboxylic acid inhibits influenza virus neuraminidase |
| Q30351638 | Avian flu: isolation of drug-resistant H5N1 virus. |
| Q43175730 | Bangkok International Conference on Avian Influenza 2008. |
| Q40086126 | Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules |
| Q30375636 | Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. |
| Q30363524 | Circulating avian influenza viruses closely related to the 1918 virus have pandemic potential. |
| Q30400049 | Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009 |
| Q35005209 | Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir |
| Q47601706 | Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir |
| Q30419391 | Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. |
| Q28364114 | Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants |
| Q30367643 | Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. |
| Q27650620 | Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants |
| Q44903223 | Current research on respiratory viral infections: Fifth International Symposium. |
| Q30373322 | Decentralized molecular diagnostic testing plan for pandemic influenza in the Ontario Public Health Laboratory system. |
| Q30391440 | Decision making with regard to antiviral intervention during an influenza pandemic |
| Q40532006 | Design, Synthesis, and Molecular Docking of Novel Pyrrolooxazepinediol Derivatives with Anti-Influenza Neuraminidase Activity |
| Q33826384 | Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance |
| Q30399501 | Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing |
| Q30308218 | Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay |
| Q30383771 | Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. |
| Q43800842 | Development and implementation of influenza a virus subtyping and detection of genotypic resistance to neuraminidase inhibitors |
| Q34253013 | Discovery and SAR study of piperidine-based derivatives as novel influenza virus inhibitors |
| Q30234600 | Drug resistance in influenza A virus: the epidemiology and management |
| Q28473959 | Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis |
| Q40004651 | Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks |
| Q28475986 | Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial |
| Q40152886 | Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial |
| Q30353989 | Emergence of drug-resistant influenza virus: population dynamical considerations. |
| Q42725866 | Emerging influenza antiviral resistance threats |
| Q30448118 | Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor |
| Q28477046 | Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards |
| Q33354941 | Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir |
| Q34339407 | Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses |
| Q30453005 | Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. |
| Q39071692 | Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro |
| Q24536333 | Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. |
| Q56378326 | Experimental infection of human volunteers |
| Q27678914 | Functional and Structural Analysis of Influenza Virus Neuraminidase N3 Offers Further Insight into the Mechanisms of Oseltamivir Resistance |
| Q30397253 | Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors |
| Q30368936 | Genetic characterization of avian influenza viruses isolated from waterfowl in southern part of South Korea in 2006. |
| Q30386561 | Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus |
| Q57002930 | H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes |
| Q51783228 | Health-seeking behavior and transmission dynamics in the control of influenza infection among different age groups. |
| Q28472513 | Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses |
| Q41929666 | Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains |
| Q30396357 | Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method |
| Q45353103 | Identification of potential inhibitors of H5N1 influenza A virus neuraminidase by ligand-based virtual screening approach |
| Q28537982 | Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study |
| Q42755170 | Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics |
| Q37392896 | In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. |
| Q64127535 | Influenza |
| Q21562135 | Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance |
| Q37542274 | Influenza genome analysis using pyrosequencing method: current applications for a moving target |
| Q28282405 | Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance |
| Q37949284 | Influenza neuraminidase: a druggable target for natural products |
| Q38188084 | Influenza reverse genetics: dissecting immunity and pathogenesis |
| Q44025966 | Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo |
| Q28540172 | Influenza virus drug resistance: a time-sampled population genetics perspective |
| Q79364186 | Influenza will not miss opportunities |
| Q33206816 | Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina) |
| Q37186725 | MERS-CoV recombination: implications about the reservoir and potential for adaptation |
| Q39671211 | Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir |
| Q40138039 | Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms |
| Q45391071 | Molecular and phylogenetic analysis of the H5N1 avian influenza virus caused the first highly pathogenic avian influenza outbreak in poultry in the Czech Republic in 2007. |
| Q30389890 | Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus |
| Q28263525 | Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors |
| Q30400621 | Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. |
| Q30398271 | Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets |
| Q30372421 | Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses |
| Q30228322 | Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children |
| Q28471814 | Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread |
| Q30400058 | Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus |
| Q30404038 | Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. |
| Q34648838 | Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient |
| Q35045959 | Neuraminidase inhibitors in pediatric patients: potential place in influenza therapy |
| Q30452889 | Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. |
| Q30367220 | Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. |
| Q30382312 | Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. |
| Q30350342 | Novel strategies for prevention and treatment of influenza. |
| Q30391319 | OpenFluDB, a database for human and animal influenza virus |
| Q30224096 | Oseltamivir (Tamiflu(®)) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review |
| Q56785849 | Oseltamivir for treatment and prophylaxis of influenza infection |
| Q30386485 | Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients. |
| Q39759213 | Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations |
| Q30399321 | Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico |
| Q34515436 | Oseltamivir: a clinical and pharmacological perspective |
| Q30452892 | Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors |
| Q30360609 | Pandemic flu. Clinical management of patients with an influenza-like illness during an influenza pandemic. |
| Q30359034 | Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Provisional guidelines from the British Infection Society, British Thoracic Society, and Health Protection Agency in collaboration with the De |
| Q30413154 | Peramivir for the treatment of influenza |
| Q34118992 | Permissive secondary mutations enable the evolution of influenza oseltamivir resistance |
| Q30450742 | Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors |
| Q40097170 | Phylogeny, Pathogenicity, and Transmission of H5N1 Avian Influenza Viruses in Chickens |
| Q34294358 | Position statement: global neuraminidase inhibitor susceptibility network |
| Q30383105 | Post-exposure prophylaxis during pandemic outbreaks |
| Q30417369 | Progress in structure-based drug design against influenza A virus |
| Q35560815 | Prospective of Genomics in Revealing Transmission, Reassortment and Evolution of Wildlife-Borne Avian Influenza A (H5N1) Viruses |
| Q30436323 | Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model |
| Q28344592 | RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza |
| Q26747157 | Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies |
| Q30409553 | Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis. |
| Q46417983 | Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses |
| Q26863710 | Recent progress in structure-based anti-influenza drug design |
| Q37169942 | Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. |
| Q30151772 | Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor |
| Q22305941 | Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors |
| Q45036693 | Resistant influenza A viruses in children treated with oseltamivir: descriptive study |
| Q28066861 | Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir |
| Q47656852 | Role of Solvation in Drug Design as Revealed by the Statistical Mechanics Integral Equation Theory of Liquids |
| Q27027408 | Safety and efficacy of peramivir for influenza treatment |
| Q57726187 | Sensitivity of H5N1 influenza viruses to oseltamivir: an update |
| Q27687973 | Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor |
| Q55003297 | Stochastic processes constrain the within and between host evolution of influenza virus. |
| Q30400232 | Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks |
| Q33582480 | Structural basis of sialidase in complex with geranylated flavonoids as potent natural inhibitors |
| Q24656213 | Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion |
| Q36870919 | Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. |
| Q30438502 | Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors |
| Q40080758 | Susceptibility of influenza A(H1N1)/pdm2009, seasonal A(H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014. |
| Q38047645 | Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection |
| Q40064817 | The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution. |
| Q40579225 | The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. |
| Q28542440 | The N-terminal fragment of a PB2 subunit from the influenza A virus (A/Hong Kong/156/1997 H5N1) effectively inhibits RNP activity and viral replication |
| Q54691269 | The Pandemic Threat of Avian Influenza Viruses |
| Q30362753 | The effect of population structure on the emergence of drug resistance during influenza pandemics. |
| Q30406360 | The global spread of drug-resistant influenza |
| Q30397216 | The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients |
| Q30356303 | The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. |
| Q30364454 | Transmission in the guinea pig model. |
| Q36411968 | Treatment of respiratory virus infections |
| Q30224656 | Two years after pandemic influenza A/2009/H1N1: what have we learned? |
| Q30402340 | Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis |
| Q55491209 | Unlocking pandemic potential: prevalence and spatial patterns of key substitutions in avian influenza H5N1 in Egyptian isolates. |
| Q37868241 | Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults |
| Q30205712 | Use of highly pathogenic avian influenza A(H5N1) gain-of-function studies for molecular-based surveillance and pandemic preparedness |
| Q43975411 | Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. |
| Q35127236 | Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study |
| Q30223401 | Virulence attenuation during an influenza A/H5N1 pandemic |
| Q30379353 | Zanamivir-resistant influenza viruses with a novel neuraminidase mutation |
| Q34492611 | Zanamivir: an update of its use in influenza |
| Q57572166 | ‘TamiGold’: phospha-oseltamivir-stabilised gold nanoparticles as the basis for influenza therapeutics and diagnostics targeting the neuraminidase (instead of the hemagglutinin) |
Search more.